
ę n ę

CLAIMS

WE CLAIM:

- 1. A vaccine, comprising:
 - a human immunodeficiency virus (HIV) vaccine candidate peptide containing an amino acid sequence selected from the group of the sequences consisting of SEQ ID NOS:1-31, 33-85, 87-109, and 111-672, in an immunologically acceptable excipient.
- 2. The vaccine of claim 1, wherein the peptide is between 8 amino acids and 50 amino acids in length.
- 3. The vaccine of claim 1, wherein the HIV vaccine candidate peptide has an amino acid sequence selected from the group of the sequences SEQ ID NO: 1-31, 33-85, 87-109, and 111-672.
- 4. The vaccine of claim 1, wherein the peptide is complexed to a carrier protein.
- 5. The vaccine of claim 1, wherein the peptide is a recombinant fusion protein.
- 6. The vaccine of claim 1, wherein the excipient is an adjuvant.
- 7. A recombinant human immunodeficiency virus (HIV) vaccine candidate peptide, comprising:
 - a peptide containing an amino acid sequence selected from the group of the sequences SEQ ID NO: 1-31, 33-85, 87-109, and 111-672, wherein the peptide is expressed from a recombinant polynucleotide.
- 8. The recombinant peptide of claim 7, wherein the recombinant polynucleotide is a naked DNA vaccine.



administering to a mammalian subject a HIV vaccine candidate peptide containing an amino acid sequence selected from the group of the sequences SEQ ID NOS: 1-31, 33-85, 87-109, and 111-672.

- 10. The method of claim 9, wherein the induction of an anti-HIV immune response is the raising of an anti-HIV antibody.
- 11. The method of claim 9, wherein the mammalian subject is a human.
- 12. The method of claim 9, wherein the administration is selected from the group consisting of orally, topically, parenterally, by viral infection, and intravascularly.

TRA 1586372v1